Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040 Bart, 1999, Contemporary management of patients with left ventricular svstolic dysfunction: results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry, Eur Heart J, 20, 1182, 10.1053/euhj.1998.1481 Cleland, 2003, The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe, part 1—patient characteristics and diagnosis, Eur Heart J, 24, 442, 10.1016/S0195-668X(02)00823-0 Cleland, 2002, Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey, Lancet, 360, 1631, 10.1016/S0140-6736(02)11601-1 Kostis, 1996, Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD): SOLVD Investigators, Am Heart J, 131, 350, 10.1016/S0002-8703(96)90365-8 Granger, 2000, Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors, Am Heart J, 139, 609, 10.1016/S0002-8703(00)90037-1 Riegger, 1999, Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil: Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators, Circulation, 100, 2224, 10.1161/01.CIR.100.22.2224 Swedberg, 1999, Candesartan in Heart Failure-Assessment of Mortality and Morbidity (CHARM): rationale and design, J Cardiac Failure, 5, 276, 10.1016/S1071-9164(99)90013-1 Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1 McMurray, 2003, Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) Programme, Eur J Heart Fail, 5, 261, 10.1016/S1388-9842(03)00052-7 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 Flather, 2000, Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients, Lancet, 355, 1575, 10.1016/S0140-6736(00)02212-1 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713 Maggioni, 2002, Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors, J Am Coll Cardiol, 40, 1414, 10.1016/S0735-1097(02)02304-5 Packer, 1996, Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group, N Engl J Med, 335, 1107, 10.1056/NEJM199610103351504 Packer, 2000 Yusuf, 1991, Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials, JAMA, 266, 93, 10.1001/jama.1991.03470010097038 Warner, 2000, Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema, Ann Pharmacol, 34, 526, 10.1345/aph.19294 Gavras, 2003, Are patients who develop angioedema with ACE inhibition at risk of the same problem with AT1 receptor blockers?, Arch Intern Med, 163, 240, 10.1001/archinte.163.2.240